Last reviewed · How we verify
Insulin Glargine Rescue Medication
Insulin glargine is a long-acting basal insulin that binds to insulin receptors to lower blood glucose by promoting glucose uptake and storage in peripheral tissues while suppressing hepatic glucose production.
Insulin glargine is a long-acting basal insulin that binds to insulin receptors to lower blood glucose by promoting glucose uptake and storage in peripheral tissues while suppressing hepatic glucose production. Used for Type 1 diabetes mellitus, Type 2 diabetes mellitus (as rescue or intensification therapy).
At a glance
| Generic name | Insulin Glargine Rescue Medication |
|---|---|
| Also known as | Lantus |
| Sponsor | Merck Sharp & Dohme LLC |
| Drug class | Long-acting basal insulin |
| Target | Insulin receptor |
| Modality | Biologic |
| Therapeutic area | Diabetes |
| Phase | Phase 3 |
Mechanism of action
Insulin glargine is a recombinant human insulin analog engineered with amino acid substitutions to provide a prolonged, peakless duration of action (up to 24 hours). It binds to the insulin receptor on muscle, adipose, and liver cells, facilitating glucose transport and utilization while inhibiting gluconeogenesis and glycogenolysis. As a rescue medication, it is used to rapidly achieve glycemic control in acute hyperglycemic states or when other agents have failed.
Approved indications
- Type 1 diabetes mellitus
- Type 2 diabetes mellitus (as rescue or intensification therapy)
Common side effects
- Hypoglycemia
- Weight gain
- Injection site reactions
- Lipodystrophy
Key clinical trials
- Safety and Efficacy of Ertugliflozin in the Treatment of Participants With Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control on Metformin and Sitagliptin (MK-8835-006; VERTIS SITA2) (PHASE3)
- Ertugliflozin and Sitagliptin Co-administration Factorial Study (VERTIS FACTORAL, MK-8835-005) (PHASE3)
- INSPIRE Diabetes Study: Basal Bolus Insulin as Primary Treatment of Type 2 Diabetes (PHASE4)
- Investigation of a Switch From Insulin Therapy to a Metformin & Saxagliptin Combination in Patients With Type 2 Diabetes Mellitus (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Insulin Glargine Rescue Medication CI brief — competitive landscape report
- Insulin Glargine Rescue Medication updates RSS · CI watch RSS
- Merck Sharp & Dohme LLC portfolio CI